Avoiding overdiagnosis in lung cancer screening: the volume doubling time strategy

Revel Marie-Pierre

Source: Eur Respir J 2013; 42: 1459-1463
Journal Issue: December

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Revel Marie-Pierre. Avoiding overdiagnosis in lung cancer screening: the volume doubling time strategy. Eur Respir J 2013; 42: 1459-1463

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Is CT-based screening for lung cancer finally ready for prime time?
Source: Annual Congress 2012 - PG18 Recent evolutions in screening and early diagnosis of lung cancer
Year: 2012



Our diagnostic time for lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 322s
Year: 2005

CT screening for lung cancer: is it ready for prime time yet or how to enhance pre-test probability?
Source: International Congress 2017 – The latest in lung cancer
Year: 2017

Evaluation of cardiovascular risk in a lung cancer screening cohort: what value does it bring?
Source: Breathe, 16 (4) 394; 10.1183/20734735.0204-2020
Year: 2020



An abnormal CT, now what: issues in the diagnosis and management of a patient with a potential lung cancer
Source: Annual Congress 2006 - MP11 - An abnormal CT, now what: issues in the diagnosis and management of a patient with a potential lung cancer
Year: 2006

Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes
Source: Eur Respir J 2010; 35: 146-151
Year: 2010



Cannabis use and lung cancer: time to stop overlooking the problem?
Source: Eur Respir J, 57 (5) 2004132; 10.1183/13993003.04132-2020
Year: 2021



Evolution in the diagnostic approach to lung cancer
Source: Virtual Congress 2021 – COVID-19 and management of lung cancer
Year: 2021


Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times
Source: Eur Respir J, 51 (6) 1800602; 10.1183/13993003.00602-2018
Year: 2018



Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times
Source: Eur Respir J, 51 (6) 1800844; 10.1183/13993003.00844-2018
Year: 2018



Check point inhibitors in peri-operative non small cell lung cancer strategy
Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?
Year: 2017


Validation of a gene-based lung cancer risk test (Respiragene) for high risk smokers: A targeted approach to early detection of lung cancer
Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach
Year: 2010

Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients?
Source: Eur Respir J 2002; 19: 464-468
Year: 2002



Factors determining early adherence to a lung cancer screening protocol
Source: Eur Respir J 2007; 30: 532-537
Year: 2007



Modern methods of diagnostics in screening of the COPD candidates for lung volume reduction surgery
Source: Eur Respir J 2006; 28: Suppl. 50, 274s
Year: 2006

Tissue is the issue and beyond: proper sampling for diagnosis and staging of lung cancer by chest physicians as well as its alternatives
Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach
Year: 2019


Implementation of lung cancer screening in Europe: the way forward
Source: Virtual Congress 2020 – Thoracic oncology
Year: 2020


The ALA/ATS implementation guide on lung cancer screening
Source: International Congress 2018 – Imminent global problems in lung cancer require joint action: time for an international alliance!
Year: 2018


Diagnostic delay time of lung cancer in a community study
Source: Annual Congress 2008 - Various aspects of thoracic oncology
Year: 2008

Tele-cancer: Reducing time-to-treatment for patients with lung cancer
Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement
Year: 2018